Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KZRNASDAQ:PULMNASDAQ:RANINASDAQ:TSBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKZRKezar Life Sciences$4.55-0.7%$4.30$3.62▼$9.18$33.46M0.652,099 shs20,285 shsPULMPulmatrix$6.66+2.0%$7.24$1.78▼$10.40N/A1.36137,438 shs6,653 shsRANIRani Therapeutics$0.54+0.2%$0.64$0.46▼$4.19$30.78M-0.02825,315 shs160,927 shsTSBXTurnstone Biologics$0.37+0.9%$0.35$0.29▼$2.69$8.37M1.35279,212 shs59,751 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKZRKezar Life Sciences-0.22%-0.66%+3.41%+13.18%-21.59%PULMPulmatrix-1.97%-3.48%-25.08%+21.76%+215.62%RANIRani Therapeutics-0.32%+4.36%-4.23%-49.41%-85.66%TSBXTurnstone Biologics+0.86%+1.70%+1.14%+1.14%-83.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKZRKezar Life Sciences4.0397 of 5 stars3.23.00.04.60.72.50.6PULMPulmatrixN/AN/AN/AN/AN/AN/AN/AN/ARANIRani Therapeutics1.4897 of 5 stars3.51.00.00.00.01.70.6TSBXTurnstone Biologics1.5715 of 5 stars1.83.00.00.00.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKZRKezar Life Sciences 2.33Hold$39.50768.13% UpsidePULMPulmatrix 0.00N/AN/AN/ARANIRani Therapeutics 3.00Buy$7.331,267.39% UpsideTSBXTurnstone Biologics 1.50Reduce$0.4523.25% UpsideCurrent Analyst Ratings BreakdownLatest TSBX, KZR, RANI, and PULM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025RANIRani TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKZRKezar Life Sciences$7M4.75N/AN/A$16.02 per share0.28PULMPulmatrix$7.81MN/AN/AN/A$2.45 per shareN/ARANIRani Therapeutics$1.20M25.69N/AN/A$0.06 per share8.94TSBXTurnstone BiologicsN/AN/AN/AN/A$1.36 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)PULMPulmatrix-$6.94M-$3.34N/A∞N/A-122.46%-94.97%-84.57%8/12/2025 (Estimated)RANIRani Therapeutics-$30.02M-$0.99N/AN/AN/AN/A-1,258.76%-80.52%8/5/2025 (Estimated)TSBXTurnstone Biologics-$70.84M-$2.73N/AN/AN/AN/A-162.79%-124.10%8/13/2025 (Estimated)Latest TSBX, KZR, RANI, and PULM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025RANIRani Therapeutics-$0.19N/AN/AN/AN/AN/A5/15/2025Q1 2025PULMPulmatrixN/A-$0.50N/A-$0.50N/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/13/2025Q1 2025RANIRani Therapeutics-$0.22-$0.22N/A-$0.22N/A$0.20 million5/8/2025Q1 2025TSBXTurnstone Biologics-$0.26-$0.51-$0.25-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKZRKezar Life SciencesN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ATSBXTurnstone BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKZRKezar Life Sciences0.047.097.09PULMPulmatrixN/A8.908.90RANIRani Therapeutics2.750.880.88TSBXTurnstone BiologicsN/A3.703.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKZRKezar Life Sciences67.90%PULMPulmatrix11.84%RANIRani Therapeutics30.19%TSBXTurnstone Biologics52.51%Insider OwnershipCompanyInsider OwnershipKZRKezar Life Sciences9.30%PULMPulmatrix0.62%RANIRani Therapeutics50.42%TSBXTurnstone Biologics32.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKZRKezar Life Sciences607.31 million6.63 millionNot OptionablePULMPulmatrix20N/AN/ANot OptionableRANIRani Therapeutics11057.48 million26.84 millionOptionableTSBXTurnstone Biologics8223.14 million15.71 millionNot OptionableTSBX, KZR, RANI, and PULM HeadlinesRecent News About These Companies$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)June 30, 2025 | globenewswire.comTurnstone Biologics Corp. Enters Merger Agreement with XOMAJune 27, 2025 | tipranks.comXOMA stock rises after acquisition of Turnstone BiologicsJune 27, 2025 | au.investing.comTurnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment SlumpsJune 27, 2025 | msn.comTSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to ShareholdersJune 27, 2025 | businesswire.comTurnstone Biologics Corp. (TSBX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...May 8, 2025 | gurufocus.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate HighlightsMay 8, 2025 | globenewswire.comTurnstone Biologics reports Q4 EPS (56c) vs (73c) last yearMarch 31, 2025 | markets.businessinsider.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | investing.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | globenewswire.comTurnstone Biologics stock plunges to 52-week low of $0.4February 11, 2025 | msn.comTurnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?February 7, 2025 | zacks.comTurnstone Biologics to explore strategic alternativesFebruary 6, 2025 | thepharmaletter.comTTurnstone ends last remaining clinical program due to costs, plots more layoffsFebruary 5, 2025 | fiercebiotech.comFTurnstone Biologics halts TIDAL-01 development, seeks alternativesFebruary 5, 2025 | msn.comTurnstone Biologics downgraded to Neutral from Overweight at Piper SandlerFebruary 5, 2025 | markets.businessinsider.comTurnstone Biologics Corp (TSBX) Stock: A Deeper Look at Its True PotentialFebruary 5, 2025 | bovnews.comBTurnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives ReviewFebruary 4, 2025 | quiverquant.comQTurnstone Biologics Announces Plans to Explore Strategic AlternativesFebruary 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeIran Conflict Fuels Fertilizer Stocks’ Bullish SetupBy Gabriel Osorio-Mazilli | June 16, 2025View Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeBy Nathan Reiff | June 9, 2025View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a SurgeTSBX, KZR, RANI, and PULM Company DescriptionsKezar Life Sciences NASDAQ:KZR$4.55 -0.03 (-0.66%) As of 07/7/2025 04:00 PM EasternKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Pulmatrix NASDAQ:PULM$6.66 +0.13 (+1.99%) As of 07/7/2025 03:58 PM EasternPulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Rani Therapeutics NASDAQ:RANI$0.54 +0.00 (+0.17%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.54 +0.00 (+0.32%) As of 07:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Turnstone Biologics NASDAQ:TSBX$0.37 +0.00 (+0.91%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.36 0.00 (-0.85%) As of 07/7/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
